Corporate Round - Dren Bio
Investment Firm
Overview
Dren Bio focuses on protein engineering technologies for depletion of cells, protein aggregates, and other disease-causing agents.
Announced Date
Jul 24, 2024
Funding Type
Corporate Round
Highlights
Location
United States, North America
Social
Investor Lead
Participant Investors
1
| Investor Name |
|---|
 Novartis |
Round Details and Background
Dren Bio raised $25000000 on 2024-07-24 in Corporate Round
Dren Bio focuses on protein engineering technologies for depletion of cells, protein aggregates, and other disease-causing agents.
Company Funding History
5
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Oct 16, 2020 |  Series A - Dren Bio | 7 | - | 60.0M |
| Oct 20, 2021 | Series A - Dren Bio | 1 | - | undefined |
| Jun 14, 2022 | Series B - Dren Bio | 12 | - | 65.0M |
| Jul 24, 2024 | Corporate Round - Dren Bio | 1 | - | 25.0M |
Recent Activity
News
Jul 24, 2024
BioPharma Dive - Novartis invests in bispecifics for cancer; Bob Langer steps down from Moderna board
News
Jul 24, 2024
Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer
News
Jul 24, 2024
Fierce Biotech - Novartis hopes for better luck with bispecifics via $150M upfront Dren Bio deal
News
Jul 24, 2024
Endpoints News - Novartis pays $150M upfront, including $25M in equity, for Dren Bio’s bispecifics
News
Jul 24, 2024
Business Wire - Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer